Preview

Filin’s Clinical endoscopy

Advanced search

Gastroesophageal reflux disease: basic principles of treatment

Abstract

Gastroesophageal reflux disease (GERD), characterized mainly by symptoms of heartburn and/or regurgitation, is one of the most common gastrointestinal diseases, which is usually treated by gastroenterologists and primary care physicians. Almost all countries have seen an increase in the prevalence of GERD, especially in North America, East Asia, and European countries, including Russia. Every 5 years, the incidence of GERD increases by 1.5-2%. Thus, according to forecasts, by 2030, 80% of the population in the United States will suffer from GERD. A review of foreign and domestic literature showed that the prevalence of GERD ranges from 1,000 to 1,000 in East Asia, North America, and European countries to 1,000. The reasons for the increase in its frequency include: physical inactivity, smoking, genetic predisposition, changes in the structure and quality of nutrition, and an increased body mass index. Approximately 80% of patients with GERD undergo conservative treatment, among which the leading place belongs to proton pump inhibitors (PPIs), about 10% of patients undergo surgical treatment. In addition, in the last decade, there have been significant changes in approaches to the treatment of GERD, an increase in the number of reports of adverse events associated with long-term use of PPIs, a noticeable decrease in the use of surgical fundoplication, and an increase in the development of non-drug intraluminal endoscopic techniques.

About the Author

V. O. Timoshenko
Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky
Russian Federation


References

1. Austin GL, Thiny MT, Westman EC, Yancy Ws Jr, Shaheen NJ. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51(8):1307-1312.

2. Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(3):105-112.

3. Baik D, Sheng J, Schlaffer K, Friedenberg FK, Smith MS, Ehrlich AC. Abdominal diameter index is a stronger predictor of prevalent Barrett’s esophagus than BMI or waist-to-hip ratio. Dis Esophagus. 2017;30(9):1-6.

4. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798-1810.

5. El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009; 104(9):2161-2167.

6. Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol. 2006;4(1):50-56.

7. Fass R. The relationship between gastroesophageal reflux disease and sleep. Curr Gastroenterol Rep. 2009; 11(3):202-208.

8. Fuentes AV, Pineda MD, Venkata KCN.Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy. 2018; 6(2):43.

9. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; 108(3):308-328.

10. Kramer JR, Fischbach LA, Richardson P, et al. Waist-tohip ratio, but not body mass index, is associated with an increased risk of Barrett’s esophagus in white men. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol

11. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA. 2020;324(24):2536-2547.

12. Mone I, Kraja B, Bregu A, et al. Adherence to a predominantly Mediterranean diet decreases the risk of gastroesophageal reflux disease: a cross-sectional study in a South Eastern European population. Dis Esophagus. 2016; 29(7):794-800.

13. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(s2):2-8.

14. Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion. 1977;15(2):104-109.

15. Targownik L. Discontinuing long-term PPI therapy: why, with whom, and how? Am J Gastroenterol. 2018;113(4):519-528.

16. Vioque J, Barber X, Bolumar F, et al. Esophageal cancer risk by type of alcohol drinking and smoking: a case-control study in Spain. BMC Cancer. 2008;8:221-221.

17. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15(9):1351-1356.


Review

For citations:


Timoshenko V.O. Gastroesophageal reflux disease: basic principles of treatment. Filin’s Clinical endoscopy. 2024;66(1):29-38. (In Russ.)

Views: 54


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2415-7813 (Print)